Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225741 | 0.94 | NR1I2 (0.35) | NR1I2KCNH2LTB4R | |
| SCHEMBL18868804 | 0.94 | KCNH2 (0.41) | NR1I2KCNH2LTB4RGPR84 | |
| SCHEMBL19492509 | 0.94 | KCNH2 (0.41) | NR1I2KCNH2LTB4RGPR84 | |
| SCHEMBL23666479 | 0.91 | KCNH2 (0.39) | NR1I2KCNH2LTB4RGPR84 | |
| SCHEMBL20932716 | 0.83 | GPR84 (0.47) | KCNH2GPR84 | |
| SCHEMBL22681518 | 0.81 | NR1I2 (0.39) | NR1I2KCNH2LTB4RPRSS1PRSS2 | |
| SCHEMBL22684510 | 0.81 | MCHR1 (0.40) | NR1I2KCNH2 | |
| SCHEMBL24805768 | 0.78 | GPR84 (0.43) | NR1I2GPR84 | |
| SCHEMBL23510582 | 0.78 | NR1I2 (0.37) | NR1I2KCNH2 | |
| SCHEMBL23347040 | 0.76 | KCNH2 (0.42) | NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284632-A1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284632-A1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1B1, GUCY1B2, GUCY1A2 | NR1I2 4275/4885KCNH2 1177/4885LTB4R 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.